Table 1. Effect of chronic JZL184 treatment on the brain levels of endocannabinoids and their metabolites.
| 2N | Ts65Dn | |||||
| Veh | JZL184 | JZL184 | Veh | JZL184 | JZL184 | |
| 8 mg/kg | 40 mg/kg | 8 mg/kg | 40 mg/kg | |||
| 2-AG | 100±8.8 | 392.9±47.4 a | 547.8±50.1a | 148.0±15.8 a | 451.0±47.7 a,b | 572.0±23.1 a,b |
| AEA | 100±11.9 | 112.2±19.2 | 270.9±38.5 a | 115.7±12.9 | 133.5±21.1 | 248.9±24.8 a,b |
| AA | 100±9.1 | 30.3±2.3 a | 20.1±1.7 a | 91.4±4.1 | 27.7±3.0 a,b | 23.9±1.2 a,b |
| PGD2 | 100±13.0 | 22.9±3.0 | 8.1±3.4 a | 89.3±4.9 | 17.6±2.0 a,b | 8.1±1.4 a,b |
| PGE2 | 100±14.1 | 29.0±4.4 a | 16.1±3.9 a | 85.3±8.9 | 34.3±5.0 a,b | 25.0±4.4 a,b |
| PGFα | 100±13.9 | 26.8±4.0 a | - | 84.7±8.5 | 36.3±7.4 a,b | - |
| PGJ2 | 100±13.7 | 33.6±5.4 a | - | 89.3±6.1 | 32.4±3.6 a,b | - |
The values are given in percents of the ‘2N Veh’ group.
a)
p<0.001. Significant difference vs. ‘2N Veh’ group.
b)
p<0.001. Significant difference vs. ‘Ts65Dn Veh’ group.